Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB2 days ago · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever
WEB2 days ago · REGN. --Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has approved Dupixent ® as an add-on maintenance treatment of adults with ...
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEB2 days ago · With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB2 days ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA) and Regeneron's (REGN.O) blockbuster drug Dupixent for patients with a chronic lung disease, commonly known...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB2 days ago · Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBSep 11, 2024 · Dupixent, which was invented using Regeneron’s proprietary VelocImmune ® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown …
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant …
WEBSep 11, 2024 · More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines. Data will support regulatory resubmission in the U.S. by year-end; if approved, Dupixent would be the first targeted therapy for CSU in a decade.
Regeneron, Sanofi Get FDA OK of Dupixent for COPD — Update
WEB2 days ago · Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and...
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB14 hours ago · The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEB(Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the...
Skip to content